Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | USP2 | O75604 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | PLEC | Q15149 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 14/20 | 0.47 |
| ▸ | CA2 | P00918 | 14/20 | 0.47 |
| ▸ | CA9 | Q16790 | 14/20 | 0.47 |
| ▸ | CA12 | O43570 | 5/20 | 0.45 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | ALPG | P10696 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17833664 | 0.90 | USP2 (0.64) | MEN1KMT2AUSP2POLBATM | |
| SCHEMBL19788026 | 0.85 | CA9 (0.62) | USP2CA1CA2CA9CA12 | |
| SCHEMBL16103947 | 0.82 | USP2 (0.62) | MEN1KMT2AUSP2POLBATM | |
| SCHEMBL10205352 | 0.81 | POLB (0.47) | MEN1KMT2AUSP2POLBATM | |
| SCHEMBL10031014 | 0.79 | USP2 (0.60) | MEN1KMT2AUSP2POLBATM | |
| SCHEMBL19817548 | 0.79 | USP2 (0.60) | MEN1KMT2AUSP2POLBATM | |
| SCHEMBL9910747 | 0.78 | MEN1 (0.72) | MEN1KMT2AUSP2POLBATM | |
| SCHEMBL14510941 | 0.78 | USP2 (0.59) | MEN1KMT2AUSP2POLBATM | |
| SCHEMBL10035689 | 0.78 | USP2 (0.59) | MEN1KMT2AUSP2POLBATM | |
| SCHEMBL14044262 | 0.76 | USP2 (0.77) | MEN1KMT2AUSP2POLBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160166679-A1 | METHOD OF TREATMENT USING FOLATE CONJUGATES AND TYROSINE KINASE INHIBITORS | PURDUE RESEARCH FOUNDATION | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166679-A1 | METHOD OF TREATMENT USING FOLATE CONJUGATES AND TYROSINE KINASE INHIBITORS | DHFR, FOLR1, FER | MEN1 1476/4885KMT2A 558/4885USP2 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.